Ryaltris US Debut Plan, Generic Spiriva Fuel Buoyant Glenmark Outlook

Glenmark Pharmaceuticals Limited’s Ryaltris (olopatadine/mometasone furoate nasal spray) is headed for a debut in the US in the coming months and the Indian firm’s management put forth a buoyant outlook for the rhinitis therapy with expectations of triple-digit peak sales globally.

Glenmark expects Ryaltris to hit the US market in the first quarter of fiscal 2023 via partner Hikma Pharmaceuticals plc, even as the product gains traction in many other international markets, where it has already been